07Feb 2025
Apical Patency Does Not Cause Osteonecrosis in Zoledronic Acid or Denosumab Treated Rats

Apical Patency Does Not Cause Osteonecrosis in Zoledronic Acid or Denosumab Treated Rats

Apical patency (AP) in rats treated with Zoledronic Acid (ZA) or Denosumab (DMAB) did not cause osteonecrosis of the jaw. While no clinical signs of osteonecrosis were observed, significant changes in bone microarchitecture were seen, especially in the ZA-AP group, which showed lower bone volume and mineral density compared to the ZA group. However, these changes were not linked to osteonecrosis. Apical patency did not impact bone integrity in the DMAB groups.

  • #dentistry

Like

Save

Share